Cerity Partners LLC Purchases New Position in Sotera Health (NASDAQ:SHC)

Cerity Partners LLC purchased a new stake in Sotera Health (NASDAQ:SHC) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 89,159 shares of the company’s stock, valued at approximately $1,489,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. William Blair Investment Management LLC grew its stake in Sotera Health by 0.6% in the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock valued at $13,430,000 after buying an additional 6,707 shares during the last quarter. Clearline Capital LP acquired a new position in Sotera Health in the 2nd quarter valued at about $1,707,000. First Pacific Advisors LP acquired a new position in Sotera Health in the 2nd quarter valued at about $540,000. Darsana Capital Partners LP bought a new stake in Sotera Health in the 2nd quarter valued at about $29,074,000. Finally, Bank of New York Mellon Corp boosted its holdings in Sotera Health by 3.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,004,046 shares of the company’s stock valued at $11,918,000 after purchasing an additional 37,681 shares during the period. Institutional investors and hedge funds own 91.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SHC. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st. Citigroup boosted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Barclays boosted their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Insider Buying and Selling at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. This represents a 16.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 55.12% of the company’s stock.

Sotera Health Stock Performance

Shares of Sotera Health stock opened at $12.83 on Wednesday. The company has a 50 day moving average of $15.10 and a 200-day moving average of $14.07. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The company has a market cap of $3.63 billion, a PE ratio of 51.32 and a beta of 1.96.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. Sotera Health’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.18 earnings per share. As a group, equities research analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.